Every 8-K that Leap Therapeutics, Inc. (LPTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LPTX filings page.
Cypherpunk Technologies Inc. reports that it has regained compliance with Nasdaq’s minimum bid price requirement for its common stock. Nasdaq notified the company on May 21, 2026 that it now meets Nasdaq Listing Rule 5550(a)(2), and Nasdaq considers the matter closed.
The company had previously received a deficiency letter on March 4, 2026 after its closing bid price stayed below $1.00 per share for 30 consecutive business days. Regaining compliance reduces the risk of delisting from The Nasdaq Capital Market for this specific rule.
Cypherpunk Technologies reported a much larger net loss for the first quarter of 2026 as its Zcash-focused digital asset strategy faced a sharp price drop. Net loss was $77.2 million for the quarter ended March 31, 2026, compared with $15.4 million a year earlier, driven mainly by a $77.6 million unrealized loss on the fair value of its ZEC treasury holdings as ZEC fell from $508.09 to $240.47.
Operating expenses shifted significantly, with research and development dropping to $0.2 million from $12.9 million as clinical trials were completed, while general and administrative expenses rose to $4.7 million from $3.0 million due largely to RSU-based compensation. Cash and cash equivalents were $6.7 million on March 31, 2026, and ZEC treasury holdings classified as digital assets receivable were valued at $73.8 million based on the quarter-end ZEC price.
Cypherpunk Technologies reported a sharp turnaround for 2025, posting net income of $4.8 million after a net loss of $67.8 million in 2024. Results were driven mainly by a $50.4 million unrealized gain on the fair value of its Zcash (ZEC) digital asset treasury.
Operating expenses fell as research and development dropped to $25.7 million and general and administrative to $10.9 million, helped by reduced clinical and payroll costs following completion of the sirexatamab Phase 2 program and headcount reductions. At year-end 2025, cash and cash equivalents were $14.0 million, while ZEC treasury holdings recorded as a digital asset receivable totaled $147.4 million, reflecting the company’s new privacy-technology and Zcash-focused strategy funded by a prior $58.88 million private placement.
Cypherpunk Technologies Inc. received a notice from Nasdaq that its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).
The notice is a deficiency warning, not an immediate delisting, and the stock continues to trade on the Nasdaq Capital Market. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days, and may qualify for an additional 180-day period if other listing standards are met.
Cypherpunk plans to monitor its share price and may pursue options such as a reverse stock split to restore compliance, but there is no assurance it will succeed within the initial or any additional compliance period.
Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.
Cypherpunk Technologies Inc. (NASDAQ: LPTX) established an at-the-market equity program, allowing sales of common stock of up to $200,000,000 through Cantor Fitzgerald & Co., which may act as sales agent or principal.
Sales may be made from time to time as “at the market offerings” under Rule 415. Cantor will receive a commission of up to 3.0% of gross proceeds. The company can suspend offers at any time, and either party may terminate the agreement with ten business days’ notice. Shares will be issued off the company’s effective Form S-3 shelf, with sales made pursuant to a prospectus supplement. The company also noted its corporate name change to Cypherpunk Technologies Inc., effective November 12, 2025.
Cypherpunk Technologies Inc. (formerly Leap Therapeutics) announced a rebrand, leadership changes, large equity awards, and a new digital-asset treasury approach. The company used $50 million of private placement proceeds to buy 203,775 ZEC at a weighted average cost of $245.37 per token. Its Nasdaq ticker will change from LPTX to CYPH, effective at the market open on November 13, 2025.
The board appointed Khing Oei (non-executive Chairman) and William McEvoy as directors, with Mr. McEvoy also named Chief Investment Officer and eligible for 5,616,906 RSUs, subject to stockholder and plan-related approvals. A consulting agreement with CoinXit Ltd. includes an immediate grant of 2,411,700 RSUs and a contingent grant of 3,036,457 RSUs upon specified approvals. The compensation committee also approved an aggregate of 3,241,687 RSUs for directors and employees. The company adopted amended bylaws, formed a new subsidiary retaining the Leap Therapeutics name for R&D operations, and furnished Q3 2025 results via press release.
Leap Therapeutics, Inc. filed an 8-K reporting a material event that attaches a resale registration statement and related agreements and exhibits. The filing specifies that the Resale Registration Statement must be kept continuously effective from the SEC effectiveness date until either the purchasers have resold all registrable securities or those securities become freely tradable under Rule 144 without volume or manner-of-sale limits and without reliance on the current public information requirement. The filing includes forms for a Common Warrant, Pre-Funded Warrant, a Securities Purchase Agreement, a Registration Rights Agreement, a Lead Investor Agreement, and a Press Release dated October 9, 2025. The document notes procedural timing tied to SEC operations (effectiveness timing can extend if the SEC is closed).
Leap Therapeutics, Inc. reported that it has entered into a private placement and adopted a new digital asset treasury strategy. The company plans to maintain its existing biopharmaceutical business while also pursuing this digital asset approach to managing part of its treasury. These developments were first described in a press release dated October 6, 2025, which is attached as an exhibit to the report.
Leap Therapeutics, Inc. received an additional 180-day grace period from Nasdaq, until March 9, 2026, to regain compliance with the Nasdaq Capital Market’s $1.00 minimum bid price requirement for its common stock. The extension was granted because the company met all other initial listing standards, including the market value of publicly held shares.
During this second compliance period, Leap Therapeutics could still be delisted if it fails to satisfy other Nasdaq listing rules. The company plans to monitor its share price and may consider a reverse stock split to restore compliance, but there is no assurance it will succeed or avoid eventual delisting.
Leap Therapeutics, Inc. (LPTX) filed a Form 8-K reporting an item related to Results of Operations and Financial Condition and furnished a press release as an exhibit. The filing identifies Item 9.01 (Financial Statements and Exhibits) and lists Exhibit 99.1 as a press release dated August 14, 2025. The disclosure is signed by Douglas E. Onsi, Chief Executive Officer and President. The document does not include financial statements, earnings figures, transaction details, or other substantive operational data within the provided text.